CD4 T-cell platform for delivering interferons as an antiviral countermeasure with a focus on SARS-CoV-2

Read full text Summarise with VIRAT
Authors: Xiaohe Liu, Marvin A. Ssemadaali, Harikrishnan Radhakrishnan, Juan Arredondo, Harold S. Javitz, Satya Dandekar, Parijat Bhatnagar
Cited by: 0
References: 74

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Vaccines prevent the incidence of new infections, but availability of interventions that can prevent transition to severe disease is limited. Interferons (IFN) serve an important part of anti-viral host immune defense. Viruses including SARS-CoV-2 dysregulate IFN kinetics, leading to pathogenesis. The efficacy of systemically infused IFNs as a viable antiviral intervention is compromised by their adverse side effects and restrict the acceptable dosage levels. To address this problem, CD4 T cells have been engineered into a cell-based delivery platform that synthesizes antiviral IFNs upon recognizing the envelope protein of SARS-CoV-2. This pathway cannot be disrupted by viruses and delivers the IFNs directly where needed, reducing side effects. Prophylactic and therapeutic effects of the type-I and type-III IFNs, produced from the T-cell delivery platform, on SARS-CoV-2-infected host cells have been determined. Among the tested interferons, type-I IFN-β consistently exhibited the strongest antiviral activity. The platform is based on CD4 T cells engineered with chimeric antigen receptors and can be rapidly re-engineered for targeting any new pathogen with sensitivity toward IFNs.

Fields of Study & Subjects

SARS-CoV-2 and COVID-19 Research interferon and immune responses CAR-T cell therapy research

Publication details

Journal / source
Molecular Medicine
Volume
32
Issue
1
Publication date
28 March 2026
Language
EN